Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO) Revenue
Annual & quarterly revenue history · segment & region breakdown
ALBO · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAlbireo Pharma, Inc. trailing twelve-month (TTM) revenue is $0.06B, an increase of 388.43% year-over-year from $0.04B in FY2021.
Revenue trend
2021 – 2004 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2021-12-31 | $0.04B | +$0.03B | +388.43% |
| 2020-12-31 | $0.01B | -$0.00B | -13.78% |
| 2019-12-31 | $0.01B | -$0.00B | -24.36% |
| 2018-12-31 | $0.01B | +$0.01B | +1273900.00% |
| 2017-12-31 | $0.00B | -$0.01B | -99.99% |
| 2016-12-31 | $0.01B | +$0.01B | — |
| 2015-09-30 | $0.00B | +$0.00B | — |
| 2014-09-30 | $0.00B | +$0.00B | — |
| 2013-09-30 | $0.00B | +$0.00B | — |
| 2012-09-30 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare ALBO revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Albireo Pharma, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Albireo Pharma, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Albireo Pharma, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ALBO revenue · 4 questionsALBO's trailing twelve-month (TTM) revenue is $0.06B. That is an increase of 388.43% year-over-year from $0.04B in FY2021.
▸ Source: FMP · Albireo Pharma, Inc. SEC filings · GAAP · Albireo Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026